Editorial
Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4–5 chronic kidney disease
Abstract
The prevalence of Hepatitis C (HCV) in patients with advanced renal disease and dialysis is higher than that of general population with rates around 5–10% in Europe and USA (1,2).
